Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th anniversary this month since its release by Ono Pharmaceutical Co. under the brand name Opdivo.But while it is highly effective in treating multiple types of cancer, its extremely high price has reignited the debate over how best to deal with expensive drugs, balancing the financial burden on the healthcare system and patients with the need for pharmaceutical firms to have the incentive to produce life-saving new drugs."If there had been even the slightest delay in approval …READ FULL ARTICLE
